126767-63-3

Basic information

• Product Name: 4-(difluoromethoxy)benzohydrazide
• Synonyms: 4-(difluoromethoxy)benzohydrazide
• CAS NO: 126767-63-3
• Molecular Formula: C₈H₈F₂N₂O₂
• Molecular Weight: 202.1581264
• Mol File: 126767-63-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(difluoromethoxy)benzohydrazide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(difluoromethoxy)benzohydrazide(126767-63-3)
• EPA Substance Registry System: 4-(difluoromethoxy)benzohydrazide(126767-63-3)

Safety Data

• Hazardous Substances Data: 126767-63-3(Hazardous Substances Data)

Upstream product

• 4837-20-1 4-(difluoromethoxy)benzoic acid 

Downstream Products

• 863646-96-2 3-[3-(3-chloro-phenyl)-[1,2,4]oxadiazol-5-yl]-4-[5-(4-difluoromethoxy-phenyl)-4-methyl-4H-[1,2,4]triazol-3-yl]-piperazine-1-carboxylic acid tert-butyl ester 
• 1254036-03-7 ethyl 5-[4-(difluoromethoxy)phenyl]-1,3,4-oxadiazole-2-carboxylate 

Relevant articles and documents

SAR Studies on Aromatic Acylhydrazone-Based Inhibitors of Fungal Sphingolipid Synthesis as Next-Generation Antifungal Agents

Recently, the fungal sphingolipid glucosylceramide (GlcCer) synthesis has emerged as a highly promising new target for drug discovery of next-generation antifungal agents, and we found two aromatic acylhydrazones as effective inhibitors of GlcCer synthesis based on HTP screening. In the present work, we have designed libraries of new aromatic acylhydrazones, evaluated their antifungal activities (MIC80 and time-kill profile) against C. neoformans, and performed an extensive SAR study, which led to the identification of five promising lead compounds, exhibiting excellent fungicidal activities with very large selectivity index. Moreover, two compounds demonstrated broad spectrum antifungal activity against six other clinically relevant fungal strains. These five lead compounds were examined for their synergism/cooperativity with five clinical drugs against seven fungal strains, and very encouraging results were obtained; e.g., the combination of all five lead compounds with voriconazole exhibited either synergistic or additive effect to all seven fungal strains.

INHIBITORS OF RHO/MRTF/SRF-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME

Disclosed herein are inhibitors of Rho/MRTF/SRF-mediated gene transcription, and methods for their use in treating or preventing diseases such as cancer and fibrosis. In particular, disclosed herein are compounds of Formula (I) and pharmaceutically accept

POLYHETEROCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS

The present invention relates to new compounds of formula (I), wherein P, Q, X1, X2, X3, X4, X5, X6, R1, R2, R3, m, n, and p are as defined as in formula (I), or salts, or hydrates thereof, processes for their preparation and new intermediates used in the preparation thereof, pharmaceutical compositions containing said compounds and to the use of said compounds in therapy.

Triazole derivatives

The present invention relates to triazole and imidazole derivatives of formula I and to their pharmaceutically acceptable acid addition salts. These compounds are NMDA receptor subtype blockers and are useful for the treatment of diseases related to the NMDA receptor.